Positron hits the ropes

Article

PET vendor Positron could be headed for bankruptcy. An independent auditor has expressed "substantial doubt" that the company, which was among the pioneers of positron imaging, could continue much longer as a "going concern." The auditor's comments were

PET vendor Positron could be headed for bankruptcy. An independent auditor has expressed "substantial doubt" that the company, which was among the pioneers of positron imaging, could continue much longer as a "going concern." The auditor's comments were reported in Positron's annual report, filed March 29 with the Securities and Exchange Commission. As of Dec. 31, 2001, the company had cash and cash equivalents of $635,000 compared with cash and cash equivalents and short-term investments of $2,201,000 a year earlier. Positron has accumulated a deficit of more than $54 million since its inception in 1983, according to the auditor's statement. Only about 19 of the company's Posicam PET scanners are currently in operation, 15 of them in the U.S. The company must increase system sales to become profitable, something it has not been able to do in its 20-year history, or obtain additional capital, according to the auditor.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.